Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
J. Immunol., Sep;179(5):2815-23 (2007)
Monoclonal antibodies in therapy of solid tumors.
Surg. Oncol. Clin. N. Am., Oct;16(4):775-92, viii (2007)
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.
Cancer Biol. Ther., Nov;6(11):1691-9 (2007)
Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development.
Biomark Med., Apr;2(2):137-45 (2008)
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Am. J. Clin. Oncol., Feb;31(1):1-5 (2008)
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
J. Immunol., May;180(9):6392-401 (2008)
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Pancreas., Aug;37(2):154-8 (2008)
Mechanisms of tumor resistance to EGFR-targeted therapies.
Expert Opin. Ther. Targets., Mar;13(3):339-62 (2009)
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Am. J. Clin. Oncol., Feb;34(1):70-5 (2011)
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.
Sci Signal., 3(140):ra67 (2010)
Monoclonal antibody therapy of cancer.
Nat. Biotechnol., Sep;23(9):1147-57 (2005)
Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Clin Colorectal Cancer., Nov;5 Suppl 2:S71-80 (2005)
Fully human therapeutic monoclonal antibodies.
J. Immunother., 29(1):1-9 (2006)
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Cancer Biother. Radiopharm., Dec;20(6):603-13 (2005)
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
Ann. Surg. Oncol., Feb;13(2):214-20 (2006)
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
Clin. Cancer Res., Mar;12(5):1599-605 (2006)
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.
Clin Colorectal Cancer., Jul;6(2):125-32 (2006)
Targeted therapies in solid tumors: monoclonal antibodies and small molecules.
Hum Antibodies., 15(3):103-11 (2006)
Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
J. Immunother., 30(4):455-67 (2007)
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Int. J. Radiat. Oncol. Biol. Phys., Oct;69(2):358-63 (2007)